
Novartis’s prostate cancer drug 177Lu-PSMA-617 granted FDA breakthrough designation
Data from trial show the potential first-in-class radioligand therapy substantially enhanced overall survival. This comes on the back of...
Novartis’s prostate cancer drug 177Lu-PSMA-617 granted FDA breakthrough designation
FDA gives Novo Nordisk’s Wegovy the green light for treating obesity
Controversy after Biogen’s Alzheimer’s drug, Aduhelm gets accelerated FDA approval
FDA authorizes second vaccine as US cases and deaths hit records